School of Pharmaceutical Science, Shandong University, Shandong Province, People's Republic of China.
Int J Nanomedicine. 2013;8:2927-41. doi: 10.2147/IJN.S46921. Epub 2013 Aug 7.
Docetaxel has been recognized as one of the most efficient anticancer drugs over the past decade; however, its poor water solubility and systemic toxicity have greatly limited its clinical application. In recent decades, the emergence of nanotechnology has provided new drug delivery systems for docetaxel, which can improve its water solubility, minimize the side effects and increase the tumor-targeting distribution by passive or active targeting. This review focuses on the research progress in nanoformulations related to docetaxel delivery - such as polymer-based, lipid-based, and lipid-polymer hybrid nanocarriers, as well as inorganic nanoparticles - addressing their structures, characteristics, preparation, physicochemical properties, methods by which drugs are loaded into them, and their in vitro and in vivo efficacies. Further, the targeted ligands used in the docetaxel nanoformulations, such as monoclonal antibodies, peptides, folic acid, transferrin, aptamers and hyaluronic acid, are described. The issues to overcome before docetaxel nanoformulations can be used in clinical and commercial applications are also discussed.
多西他赛在过去十年中已被公认为最有效的抗癌药物之一；然而，其较差的水溶性和全身毒性极大地限制了其临床应用。近几十年来，纳米技术的出现为多西他赛提供了新的药物传递系统，通过被动或主动靶向作用，可以提高其水溶性、最小化副作用并增加肿瘤靶向分布。本综述重点介绍了与多西他赛递药相关的纳米制剂的研究进展，如基于聚合物、基于脂质和脂质-聚合物杂化的纳米载体以及无机纳米颗粒，涉及它们的结构、特性、制备、理化性质、载药方法及其体外和体内疗效。此外，还描述了多西他赛纳米制剂中使用的靶向配体，如单克隆抗体、肽、叶酸、转铁蛋白、适体和透明质酸。还讨论了在多西他赛纳米制剂能够用于临床和商业应用之前需要克服的问题。
